Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence

Samuel C. R. Sherratt
*Elucida Research LLC*

*Et al.*

Let us know how access to this document benefits you.

Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Cardiology Commons, Cardiovascular Diseases Commons, Dietetics and Clinical Nutrition Commons, Health Services Administration Commons, Lipids Commons, Molecular, Genetic, and Biochemical Nutrition Commons, Nutritional and Metabolic Diseases Commons, and the Therapeutics Commons

Repository Citation


Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence

Samuel C.R. Sherratt, Michael Lero, and R. Preston Mason

Purpose of review
The purpose of this review is to assess whether dietary fish oil supplements can be appropriate for patients with elevated triglycerides and cardiovascular risk based on a comprehensive analysis of their composition, and level of regulatory oversight.

Recent findings
Approximately 19 million people in the United States take fish oil supplements, many for the purpose of treating or preventing heart disease. Unlike prescription products, fish oil supplements are classified as food by the Food and Drug Administration (FDA) and are not required to undergo manufacturing oversight or clinical testing. Analysis of widely used dietary fish oil supplements show that they may have lower amounts of ω-3 than advertised as well as significant levels of saturated fat and oxidized oils which actually may contribute to dyslipidemia. Clinical outcome trials have failed to show a consistent cardiovascular benefit with fish oil supplements and other low-dose mixed ω-3 fatty acids.

Summary
In light of limited regulatory oversight and evidence of quality concerns, dietary fish oil supplements are not an appropriate substitute for FDA approved prescription ω-3 fatty acids for their indicated use in treatment of elevated triglycerides or the prevention of cardiovascular events.

Keywords
fish oil, oxidized lipids, supplement

INTRODUCTION
The United States Department of Health and Human Services on complementary and alternative medicine use among adults and children states that fish oil supplements are the most commonly used supplements among adults in the United States [1]. Fish consumption is recommended in the 2015–2020 Dietary Guidelines for Americans and by the American Heart Association [2]. Although widely available, fish oil supplements are not subject to approval and oversight by the Food and Drug Administration (FDA), as they are not over-the-counter (OTC) drugs, so their content and chemical integrity are not carefully regulated [3]. Additionally, their efficacy is not assessed prior to marketing as they are classified by the FDA as a food product [3]. Yet millions of consumers, including patients with dyslipidemia, take dietary fish oil supplements, many in the hopes of preventing or treating heart disease, despite the absence of supporting evidence for their clinical efficacy.

DIETARY FISH OIL SUPPLEMENT MANUFACTURING PROCESS, QUALITY, CONTENT, AND EFFICACY
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both ω-3 polyunsaturated fatty acids (O3FAs), are the valued components in fish oil...
supplements. However, these and other fatty acids are particularly susceptible to oxidation because of multiple and conjugated double bonds. There are various contributors to fatty acid oxidation, including thermal-oxidation, autoxidation, photo-oxidation, metal-catalyzed oxidation, and ionically catalyzed oxidation [4]. During the manufacturing process of fish oil supplements, fatty acids may be exposed to such oxidation pathways without careful regulatory oversight. For example, to aid in the coagulation of tissue protein and expression of the oils, the harvested fish used for these supplements are heated while exposed to atmospheric oxygen. In addition, fish oil becomes oxidized through exposure to metals and enzymes found naturally in the fish [5–7]. Primary oxidation products of fatty acids include hydroperoxides, which often degrade further into secondary oxidation products such as aldehydes and ketones. These chemical changes contribute to a loss of biological integrity of fish oil supplements and produce the easily identifiable rancid odor. During oxidation, levels of EPA and DHA decline, whereas peroxide levels increase [8], and the products of the oxidation reactions may contribute to cardiovascular risk and other chronic diseases.

Independent studies from various laboratories have verified concerns about the integrity of fish oil supplements as well as the actual levels of O3FAs compared with what is advertised. A study funded by the US Department of Agriculture found that only 10 out of 47 fish oil supplements had EPA levels at or above the dose indicated on their labels. Further, only twelve of these products reported accurate amounts of DHA, whereas 74% contained less than the stated label amounts of EPA or DHA [9]. In another study from New Zealand, 32 fish oil supplements were analyzed for fatty acid content, of which only 9% had O3FA levels that met or exceeded stated label amounts [10]. Of the total number of products tested, more than 80% were found to have levels of lipid peroxides, a biomarker of oxidation, which exceeded industry standards. Further, only 8% of the supplements met international standards for peroxide and total oxidation levels [10].

In another study, the quality of leading fish oil supplements (by sales) in the United States was compared with a prescription O3FA product with respect to EPA and DHA levels, the quantity and oxidation status of other fatty acids [11]. In addition to EPA and DHA, the supplements contained more than 30 different fatty acid variants. This included 10–14 saturated fat species that constituted up to 36% of the total fatty acid content. In one of the products, the amount of two saturated fats, palmitic acid and myristic acid, was nearly equivalent to the total EPA and DHA content (28 and 30%, respectively). The supplements were also analyzed and compared with a prescription ω-3 formulation for total oxidation (TOTOX), a composite of primary oxidation products measured as peroxide value and secondary oxidation products represented by anisidine value. The supplements exceeded the international threshold (as determined by the US Council for Responsible Nutrition) for peroxide value and TOTOX, and two of the three exceeded the threshold for anisidine value. By comparison, the FDA-approved O3FA prescription product did not have detectable levels of oxidized lipids or saturated fats. The fish oil supplement which contained a mixture of oxidized and nonoxidized EPA and DHA failed to inhibit lipoprotein oxidation compared with nonoxidized O3FAs. The data summarizing these findings can be found in Fig. 1a and b.

Similar findings with fish oil supplements and oxidation were reported in another North American study, which analyzed multiple lots of 16 fish oil supplements with respect to EPA and DHA content and oxidation levels [12]. Of the 16 products analyzed, only nine met their stated label claims for total EPA and DHA. Three of the products that failed to meet the stated EPA and DHA claims were manufactured by GOED (Global Organization for EPA and DHA) members. With regard to oxidation (measured as peroxide value), five of the products tested exceeded the limit established in the GOED Voluntary Monograph and the European Pharmacopeia Monograph. The two products that contained fatty acids (either partially or completely) as ethyl esters had the highest levels of oxidation with one having more than five times the limit.

Elevated levels of oxidized fatty acids in fish oil supplements may be expected to compromise any biological benefits. Although the favorable lipid and antiinflammatory effects of these products are often
cited as a way to prevent cardiovascular disease, these benefits may be partly or completely negated by the lipid oxidation by-products prominently found in fish oil supplements [13,14]. In a randomized controlled trial involving healthy patients, administration of oxidized fish oils over seven weeks contributed to dyslipidemia, including an elevation in non-high density lipoprotein (HDL) cholesterol levels, compared with patients administered a primarily nonoxidized fish oil [15]. The lack of therapeutic efficacy with oxidized fish oil supplements includes no improvement in lipid or inflammatory parameter levels [16] as well as blood lipid levels [17].

Beyond lipid oxidation and saturated fats in these products, there is evidence that fish oil processing technology may contribute contaminants linked to increased risk of cancer and cardiovascular disease. An analysis of oils obtained from marine fish species indicated elevated levels of dioxin and dioxin-like polychlorinated biphenyls (dl-PCBs) higher than the maximum allowable limits for human consumption [18]. Refinement of the oils with activated carbon filters significantly reduced the presence of these compounds, but not non-dioxin-like PCBs because of the lack of affinity these compounds for activated carbon. This indicates that the activated carbon alone is not sufficient for removing all harmful organic pollutants. Furthermore, results from this study showed that the refinement process increased levels of 2 and 3-monomethylpropane-1,2-diols (MCPDs) in fish oils with a higher prevalence of 3-MCPDs. This is significant because 3-MCPDs are classified as a possible human carcinogen by the International Agency for Research on Cancer. The above studies indicate that the presence of oxidized oils and other organic pollutants may be present in commercial fish oil products and thus call into question their efficacy and safety for human consumption.

**BIOLOGICAL CONSEQUENCES OF INGESTING OXIDIZED LIPIDS**

The biological consequences of ingesting oxidized lipids and the related oxidative products have been characterized in cellular and animal studies but the application to human pathology requires further investigation. For example, 13-hydroperoxyoctadecadienoic acid (13-HPODE), a product of lipid oxidation, has been shown to significantly alter cellular functions. This includes an increase in vascular adhesion molecule expression in smooth muscle cells [19], causing human endothelial cells to express both intracellular and surface adhesion molecules [20], and activating kinase expression in aortic cells [19,21]. 13-HPODE also induces inflammation by causing elevated caspase-3 activity in enteric epithelial cells and by activating MCP1 in human vascular smooth muscle cells [22–24]. Lipid peroxidation, once initiated, increases exponentially, which alters membrane fluidity, cell signaling, and cell transport [25]. Evidence also suggests that long-term lipid peroxidation may contribute to the development of various diseases, including Alzheimer’s disease and cancer [26,27]. Oxidized polyunsaturated fatty acids (PUFAs) have also been associated with hemolytic anemia, hepatomegaly, liver inflammation, and cardiomyopathy [28].
Oxidative modification of lipids has been linked to an increase in inflammation through the nuclear factor kappa-B (NF-κB) pathway [29] and insulin resistance [30,31]. The degree of oxidative stress in an organism can be quantified by measuring oxidation product levels, antioxidant levels, and the potency of antioxidant enzymes. Hydroperoxides lead to increased levels of H$_2$O$_2$ and subsequent catalase upregulation [32,33]. Multiple studies have shown that oxidized oils and their related oxidation products compromise cellular functions. One study found that treating cells with lipid hydroperoxides caused an eight-fold rise in cell apoptosis [34]. Additionally, rats fed oxidized oils had significantly lower α-tocopherol and glutathione levels in erythrocytes when compared with controls [35]. A similar study found that plasma α-tocopherol levels were reduced by 60% when pigs were fed a diet containing oxidized fats, thus compromising the endogenous antioxidant system and increasing risk for disease progression [36].

The period when oxidation of membranes and lipoproteins occurs is referred to as the lag phase and is an indicator of the antioxidant capacity of membranes and lipoproteins. The longer the lag phase, the greater the antioxidant capacity of the lipid particles [37]. Feeding rats oxidized oils can shorten low density lipoprotein (LDL) oxidation lag phase by as much as 25% [38]. In a clinical study, patients that consumed oxidized oil had a shortened plasma LDL-cholesterol oxidation lag phase by approximately 25% [39]. LDL that is more prone to oxidation has been linked to an increased risk for atherosclerosis [40–42].

Elevated levels of lipid hydroperoxides and reactive aldehydes predict cardiovascular events in patients with coronary artery disease (CAD) even after adjusting for traditional risk factors including cholesterol levels, obesity, and blood pressure [43,44]. These studies showed an increase in hospitalization for heart failure and revascularization for patients with CAD and elevated circulating lipid peroxides at baseline. In healthy patients fed oxidized oil, chylomicrons were found to have significantly higher levels of serum thiobarbituric acid-reactive substances (TBARS) when compared with controls [39].

Animal studies also provide supporting evidence for biological consequences of oxidized fatty acid consumption, including a 33% increase in plasma cholesterol levels with mice fed a diet containing oxidized O3FAs as compared with control [45]. Healthy rats fed oxidized oil rich in peroxides had a five-fold increase in serum lipoprotein peroxide levels, indicating that dietary peroxides are readily incorporated into lipoproteins [46]. Animals fed a diet containing oxidized oil also had aortic atheromas that were twice as large as the lesions found in control animals [47], whereas TBARS increased by 80% when rats were fed highly oxidized oil [48]. A separate study found that feeding mice a diet containing oxidized fat increased plasma LDL-cholesterol by 26% compared with control animals [49]. Finally, feeding rats oxidized oils resulted in increased levels of oxidation products in lipoproteins and caused the levels of oxidation products in the liver to double [50]. A similar study showed that liver levels of the antioxidant α-tocopherol were reduced by 50% in rats fed oxidized oils [51].

**CLINICAL FINDINGS FROM FISH OIL SUPPLEMENTS AND PRESCRIPTION FORMULATIONS**

Early epidemiological studies as well as outcome-based randomized clinical trials have suggested that consuming higher levels of the O3FAs may reduce the risk of heart disease [52–55]. More recent and comprehensive reviews of the clinical data with O3FAs have cast doubt on this conclusion [56*], including a recent review that examined the effectiveness of 24 supplements and diets in cardiovascular prevention [57*]. The authors evaluated nine systematic reviews and four randomized controlled trials, which encompassed 277 trials and 992 129 participants. Findings indicated that few nutritional supplements or dietary interventions offered any protection against cardiovascular disease or death. Supplementation with O3FA, in particular, yielded ‘low-certainty’ evidence that they were associated with reduced risk for myocardial infarction and coronary heart disease.

Large clinical outcome trials using a mixed and low-dose (1 g/day) O3FA have failed to demonstrate cardiovascular benefit. The ASCEND trial - A Study of Cardiovascular Disease in Diabetes trial; NCT00135226 reported the effect of 1 g/day of prescription O3FA therapy in 15 480 patients with diabetes but without evidence of atherosclerotic cardiovascular disease [58*]. The results failed to demonstrate a reduction of first serious vascular events in the O3FA arm. This is consistent with most prior studies of O3FA mixtures at low doses. A similar failure was reported in the VITAL study - Vitamin D and Omega-3 Trial; NCT01169259 among more than 25 000 patients with low cardiovascular (CV) risk using again a low-dose prescription O3FA 1 g/day [59]. In this primary prevention trial, there was no statistically significant decrease in the primary composite cardiovascular endpoint or cancer-associated endpoints. Although there was a reduction in certain secondary endpoints such as...
MI, these are only hypothesis generating and require an appropriately powered study to test. Thus, in these two studies with over 40,000 patients, there was a consistent lack using a low-dose O3FA mixture with respect to primary prevention.

In contrast to negative studies with fish oil supplements or low-dose mixed O3FA prescription products, there was a beneficial clinical outcome with a higher dose EPA-only prescription formulation. The Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial (REDUCE-IT) trial was a randomized, double-blinded, placebo-controlled trial designed to examine the benefits of icosapent ethyl, a prescription, highly purified ethyl ester of EPA at 4 g/day [60**]. The primary objective of this study was to determine if highly purified EPA treatment reduces ischemic events in statin-treated patients with elevated and high baseline fasting triglyceride (TG) levels (150–499 mg/dl) and cardiovascular risk for clinical events. The trial enrolled 8179 men and women with established atherosclerotic cardiovascular disease or with type 2 diabetes and one additional risk factor. The primary endpoint was a composite of time to first event for cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina and reported a highly statistically significant ($P < 0.001$) 25% relative risk reduction. Reductions in key secondary endpoints were also significant, including a 20% reduction in CV death, 31% reduction in MI, and a 28% reduction in stroke. Another study called STRENGTH

**FIGURE 2.** Summary of risks associated with ingestion of oxidized oils, including oxidized oils sourced from fish.
(Statins Residual Risk Reduction with Epanova in High CV Risk Patients with Hypertriglyceridemia; NCT02104817) evaluated if a 4 g/d mix of EPA and DHA was beneficial in statin-treated patients with elevated TGs. Recently, this trial was terminated due to futility at the recommendation of the independent data monitoring committee. Thus, the only O3FA proven to be of CV benefit on top of statin therapy in outcome trials remains prescription EPA.

**CONCLUSION**

Fish oil supplements are classified by the FDA as food, and thus, their approval and ongoing production does not require robust FDA review. Fish oil supplements – unlike prescription and OTC medications – do not need to demonstrate effectiveness in placebo-controlled clinical trials. Patients who consume these products are often confused by statements suggesting a benefit to cardiovascular health despite affirmative clinical evidence. In fact, a comprehensive review of the basic and clinical evidence shows that widely used fish oil supplements contain lower amounts of O3FAs than specified on the label as well as saturated fats and oxidized oils that may actually contribute to dyslipidemia and increased cardiovascular risk. Consumption of oxidized oils has been linked to increases in non-HDL cholesterol and vascular changes associated with atherosclerosis, including inflammation, LDL oxidation, and endothelial dysfunction (Fig. 2). The results of a recent study showed a significant cardiovascular benefit with a highly purified and quality-controlled prescription preparation of EPA (4 g/day). Thus, dietary fish oil supplements should not be considered an effective substitute for appropriate dosage of prescription O3FA products, which are supported by strict testing and ongoing oversight by FDA (Fig. 3).

**Acknowledgements**

The authors wish to thank Dr. Robert F. Jacob for expert scientific discussions and editorial assistance.

**Financial support and sponsorship**

None.

**Conflicts of interest**

R.P.M. acknowledges consulting and research funding from Amarin Pharma, Inc. (Amarin), Novartis, and Pfizer. The other authors have no disclosures.

**REFERENCES AND RECOMMENDED READING**

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

Genetics and molecular biology


10. Alberts RK, Miksch JM, Cameron-Smith D, et al. Fatty acids used in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep 2015; 5:7928.

11. Mason RP, Sherratt SC. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochem Biophys Res Commun 2017; 483:425–429.


33. Alberts RK, Miksch JM, Cameron-Smith D, et al. Fatty acids used in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep 2015; 5:7928.